January 17, 2024

Astellas Releases Results of Discontinued Phase 1b Study of ASP0367

Astellas has shared results of the Phase 1b study of ASP0367 (MA-0211), an oral investigational drug. The study aimed to evaluate safety, tolerability, and preliminary efficacy in individuals living with Duchenne aged 8 to 16 years old….

Learn More

November 8, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More

November 7, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More

April 22, 2022

Astellas Gene Therapies Announces plans to discontinue development of Duchenne gene therapy programs

Last night, based on recent preclinical data, Astellas Gene Therapies announced that the research and development of gene therapy programs AT702, AT751 and AT753 for Duchenne Muscular Dystrophy have been terminated. • AT702 was designed…

Learn More